Audited Supplier
Specialist Drugs, Antidiabetic Medication
GMP
Medicine Grade
API Raw Materials
Powder
C187h291n45o59
ECHEMI
Box, Bags
25kg/50kg/100kg
China
30049099
Product Description
| Product Name: | peptide-1 (GLP-1) |
| Molecular Formula: | C187H291N45O59 |
| Formula Weight: | 4113.57754 |
| Appearance: | Solid powder |
| Purity: | >98% |
| Storage: | Dry, dark, and at 0 - 4 C for the short term (days to weeks) or -20 C for the long term (months to years). |
| Solubility: | Soluble in DMS |
| Shipping Condition: | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
WHAT IS peptide-1 (GLP-1) AND HOW DOES IT WORK?
Peptide-1 (GLP-1) is a prescription medication used to treat Type 2 Diabetes Mellitus and for Weight Management
WHAT ARE DOSAGES OF peptide-1 (GLP-1)?
Adult dosage
Injection, prefilled, single-dose pen
- 2mg/1.5mL (1.34mg/mL); delivers doses of 0.25mg, 0.5mg, or 1mg per injection
- 4mg/3mL (1.34mg/mL); delivers 1 mg per injection
Injection, prefilled, single-dose pen
- 0.25mg/0.5mL
- 0.5mg/0.5mL
- 1mg/0.5mL
- 1.7mg/0.75mL
- 2.4mg/0.75mL
Oral tablet
- 3mg
- 7mg
- 14mg
Type 2 Diabetes Mellitus
Adult dosage
SC
- 0.25 mg SC once per week for 4 weeks initially; then increase to 0.5 mg per week
- If glycemic control is not achieved after at least 4 weeks on a 0.5-mg dose, can increase to 1 mg once weekly
- Note: the initial 0.25-mg dose is intended for treatment initiation and is not effective for glycemic control
Oral
- Initial: 3 mg orally once daily for 30 days; then the 3-mg dose is intended for treatment initiation and is not effective for glycemic control
- After 30 days on 3 mg/day: increase to 7 mg orally once daily
- After 30 days on 7 mg/day: may increase the dose to 14 mg orally once daily if additional glycemic control needed
- Note: Taking two 7-mg tablets to achieve a 14 mg dose is not recommended
Switching between peptide-1 (GLP-1) and Ryhelsus (orally)
- Taking 14 mg/day orally: Transition to 0.5 mg SC once weekly on the day after the last oral dose
- Taking 0.5 mg/week SC: Transition to 7 mg or 14 mg orally starting up to 7 days after last SC injection
- There is no equivalent oral dose for the 1-mg SC dose
Weight Management
Adult dosage
- Initiate with a low dose and gradually escalate to a maintenance dose of 2.4 mg/week SC to minimize GI adverse reactions
- If unable to tolerate maintenance dose of 2.4 mg once-weekly, may temporarily decrease to 1.7 mg once weekly, for a maximum of 4 weeks; after 4 weeks, increase back to maintenance 2.4 mg once-weekly; discontinue if not tolerated after the second attempt
- Weeks 1-4: 0.25 mg
- Weeks 5-8: 0.5 mg
- Weeks 9-12: 1 mg
- Weeks 13-16: 1.7 mg
- Week 17 onward: 2.4 mg (maintenance)
